RGD-4C

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

RGD-4C 是一种具有整合素结合活性的精氨酸-甘氨酸-天冬氨酸肽 (ACDCRGDCFC)。Arg-Gly-Asp (RGD) 序列是细胞外基质蛋白的主要整合素识别位点，含有该序列的多肽可以模拟基质蛋白的识别特异性。RGD-4C 是 αv 整合素配体，可与生物活性分子偶联，在动物模型中发挥抗肿瘤作用。

RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models.

RGD-4C (9.11 mg/kg; injection; single dose) inhibits the growth of B16F10 mouse melanoma in vivo.Modified RGD-4C fused with the N-terminus of plant-derived single-chain ribosome inactivating protein saporin (SAP) (called RGD-SAP), (diluted in sodium chloride, 0.9%; i.v.; 200 μL; every 5 days, for 3 times) exerts anti-tumor activity in a model of muscle invasive bladder cancer. RGD-SAP in combination with mitomycin C, a chemotherapeutic drug, increases the survival of mice bearing orthotopic bladder cancer with no evidence of systemic toxicity.

RGD-4C (2.5, 5, 10 μg/mL) inhibits BAE cell proliferation by synthetic form modified with endostatin-derived peptides.

———

Others

Other Targets

———

———

———

332179-76-7

1145.29

C42H60N14O16S4

>98% (HPLC)

DMSO : 25 mg/mL (21.83 mM; ultraphonic; )

———

———

(-20℃)

With Ice Pack

≥ 2 years